

Q-linea strengthens management team

UPPSALA, Sweden, December 14, 2021 – Q-linea today announces that the company has strengthened the management team by including Victoria Lerneryd and Ulrika Stolpe as Manager Quality Assurance and Regulatory Affairs (QA/RA) and Manager of Human Resources (HR) respectively.

"These appointments strengthen our ability to continue developing Q-linea providing value to both patients and care givers. I am very excited to have Victoria and Ulrika on board the executive management team as they will bring valuable insights to the leadership of Q-linea," says Jonas Jarvius, CEO at Q-linea.

Victoria Lerneryd joined Q-linea as QA/RA Manager in 2020 and has over 10 years of experience from Quality Assurance and Regulatory Affairs for medical devices, managing regulatory audits and submissions, quality management systems and quality assurance. Prior to Q-linea Victoria Lerneryd served as Quality Manager at St. Jude Medical and Quality & Regulatory Affairs Manager at Cavidi. Roles which included compliance responsibilities across product development, production and post-market activities.

Ulrika Stolpe joined Q-linea in 2012. Since then the company has grown from 15 to 160 employees and consultants. Ulrika Stolpe has driven the development of the company's finance and personnel-administrative processes and has also taken a large part in work environment issues. Since 2019 Ulrika Stolpe has served as Q-linea's HR manager. Prior to Q-linea Ulrika Stolpe worked with finance, HR, and office operations at small and large national and international Life science companies.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB Jonas.Jarvius@qlinea.com +46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB Anders.Lundin@qlinea.com +46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.



Attachments

Q-linea strengthens management team